AlzChem Group AG (XTER:ACT)
€ 43.3 -1.5 (-3.35%) Market Cap: 429.44 Mil Enterprise Value: 478.01 Mil PE Ratio: 10.96 PB Ratio: 2.43 GF Score: 70/100

Q1 2021 AlzChem Group AG Earnings Call Transcript

May 06, 2021 / 08:00AM GMT
Release Date Price: €25
Andreas Niedermaier
AlzChem Group AG - CEO

Good morning, everybody. Thank you for joining us today and welcome for the Q1 analyst call. As always, we start with an executive summary here and then move on to the figures after some strategic topics. At the end of the presentation, we will be available for questions. And so let's skip the disclaimer here and go directly to page 4.

Yes. So Page 4, should be available now, here we start with our presentation. So this year has started extremely positive for us, despite some background noise, with record sales and a very strong EBITDA -- we started the year with a strong tailwind.

We are seeing a noticeable recovery in the market environment across board, especially in the automotive and the steel industry. We are equally successful in further developing our pharmaceutical portfolio products with BioSelect for RNA tests and our dicyandiamide for Metformin.

Creapure, hard hit last year by the sudden decline in training activities, is back on the growth path because customers shifted their purchases to the high quality Creapure

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot